Preliminary data announced for gedatolisib from Ph 1 CELC-G-201 trial in metastatic CRPC and Ph 2 HER2+ metastatic breast cancer patients July 1, 2025
Updated data from Ph 2 DeFianCe study of sirexatamab (DKN-01) + bevacizumab and chemo combo shows statistically significant PFS improvements in DKK1-high, VEGF-naïve and liver mets MSS colorectal cancer patients July 1, 2025
ATNM-400 Demonstrates Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI and PSMA-Ac-225/Lu-177 Labelled Radiotherapy in Prostate Cancer July 1, 2025
Significant and Sustained Survival Benefit announced from Ph 2 (Actuate-1801 Part 3B) trial of elraglusib + GnP combo in 1L metastatic pancreatic adenocarcinoma July 1, 2025
80% ORR reported in injected tumours in Stage 1 of Ph 2a trial of tigilanol tiglate for Soft Tissue Sarcoma July 1, 2025
IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of 1L MCL patients eligible for autologous stem cell transplant July 1, 2025
DARZALEX® (daratumumab) receives positive CHMP opinion for patients with high-risk smouldering multiple myeloma July 1, 2025
Additional Tumor-Agnostic Indication of Alecensa for ALK Fusion/Rearrangement Gene-Positive Solid Tumors Including Pediatric Patients Filed July 1, 2025
Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors July 1, 2025
FDA Grants RMAT Designation for Detalimogene in High-Risk, Non-Muscle Invasive Bladder Cancer July 1, 2025
FDA grants Fast Track Designation for SGR-1505 for the Treatment of R/R Waldenström Macroglobulinemia July 1, 2025
NMPA approves ORPATHYS + TAGRISSO combo in China for the Treatment of Lung Cancer Patients with MET Amplification After Progression on 1L EGFR Inhibitor July 1, 2025
